Hallison Rodrigues

Title: Hallison Rodrigues: Innovator in COVID-19 Treatment

Introduction

Hallison Rodrigues is a notable inventor based in San Carlos, California. He has made significant contributions to the field of medicine, particularly in the treatment of diseases associated with hypercytokinemia, including COVID-19. With a total of three patents to his name, Rodrigues is at the forefront of innovative therapeutic methods.

Latest Patents

Rodrigues' latest patents focus on methods for treating hypercytokinemia by utilizing inhibitors of the CCR5/CCL5 interaction. One of his notable patents describes a method of treating subjects suffering from COVID-19 by administering the CCR5 antagonist maraviroc. This method includes assessing the severity of the disease by determining the level of CCL5/RANTES in a subject. Another significant patent involves the use of a human monoclonal antibody, PRO-140, which inhibits CCR5/CCL5 binding interactions to treat SARS-CoV-2-associated hypercytokinemia.

Career Highlights

Rodrigues is currently employed at Incelldx, Inc., where he continues to develop innovative solutions for treating serious health conditions. His work is characterized by a commitment to advancing medical science and improving patient outcomes.

Collaborations

Rodrigues collaborates with talented professionals in his field, including Edgar B Francisco and Amruta Pise. These partnerships enhance the research and development efforts at Incelldx, Inc., fostering an environment of innovation.

Conclusion

Hallison Rodrigues is a dedicated inventor whose work is making a significant impact in the treatment of COVID-19 and related conditions. His innovative patents and collaborations reflect his commitment to advancing medical science and improving health outcomes.